Published in Cancer Res on August 01, 2005
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat Rev Cancer (2010) 5.26
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Systemic delivery of tumor suppressor microRNA mimics using a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther (2011) 2.75
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol Cancer Res (2008) 2.21
The receptor tyrosine kinase EphA2 promotes mammary adenocarcinoma tumorigenesis and metastatic progression in mice by amplifying ErbB2 signaling. J Clin Invest (2008) 2.11
Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. J Clin Invest (2009) 2.06
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Tumour angiogenesis regulation by the miR-200 family. Nat Commun (2013) 1.90
Chemical modification: the key to clinical application of RNA interference? J Clin Invest (2007) 1.81
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Emerging strategies for EphA2 receptor targeting for cancer therapeutics. Expert Opin Ther Targets (2011) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
The clinical relevance of stromal matrix metalloproteinase expression in ovarian cancer. Clin Cancer Res (2006) 1.59
Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis. J Biol Chem (2010) 1.58
Clinical and biological significance of tissue transglutaminase in ovarian carcinoma. Cancer Res (2008) 1.55
Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy. Cancer Res (2009) 1.44
Targeted delivery of small interfering RNA using reconstituted high-density lipoprotein nanoparticles. Neoplasia (2011) 1.42
Delivery of negatively charged liposomes into the atherosclerotic plaque of apolipoprotein E-deficient mouse aortic tissue. J Liposome Res (2014) 1.40
The clinical potential of microRNAs. J Hematol Oncol (2010) 1.39
Translation regulatory factor RBM3 is a proto-oncogene that prevents mitotic catastrophe. Oncogene (2008) 1.37
Reduced adenosine-to-inosine miR-455-5p editing promotes melanoma growth and metastasis. Nat Cell Biol (2015) 1.36
Therapeutic siRNA: principles, challenges, and strategies. Yale J Biol Med (2012) 1.35
The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther (2009) 1.35
Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res (2010) 1.34
Lipidic systems for in vivo siRNA delivery. AAPS J (2009) 1.33
Engineering RNA for targeted siRNA delivery and medical application. Adv Drug Deliv Rev (2010) 1.32
Microenvironment and pathogenesis of epithelial ovarian cancer. Horm Cancer (2010) 1.30
Dual targeting of EphA2 and FAK in ovarian carcinoma. Cancer Biol Ther (2009) 1.30
Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer. Br J Cancer (2008) 1.27
RNAi therapies: drugging the undruggable. Sci Transl Med (2014) 1.26
Quantitative radioimmunoPET imaging of EphA2 in tumor-bearing mice. Eur J Nucl Med Mol Imaging (2007) 1.26
eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther (2008) 1.26
Nanoparticle-based delivery of small interfering RNA: challenges for cancer therapy. Int J Nanomedicine (2012) 1.24
Transcriptional control of melanoma metastasis: the importance of the tumor microenvironment. Semin Cancer Biol (2010) 1.23
Therapeutic synergy between microRNA and siRNA in ovarian cancer treatment. Cancer Discov (2013) 1.22
Optical imaging-guided cancer therapy with fluorescent nanoparticles. J R Soc Interface (2009) 1.22
Enhancing chemotherapy response with sustained EphA2 silencing using multistage vector delivery. Clin Cancer Res (2013) 1.21
Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol (2006) 1.21
Metabolic shifts toward glutamine regulate tumor growth, invasion and bioenergetics in ovarian cancer. Mol Syst Biol (2014) 1.21
Nanovector delivery of siRNA for cancer therapy. Cancer Gene Ther (2012) 1.19
Identification of novel therapeutic targets in microdissected clear cell ovarian cancers. PLoS One (2011) 1.18
Effectiveness of siRNA uptake in target tissues by various delivery methods. Surgery (2007) 1.17
Triggered release of siRNA from poly(ethylene glycol)-protected, pH-dependent liposomes. J Control Release (2008) 1.16
Nanopreparations to overcome multidrug resistance in cancer. Adv Drug Deliv Rev (2013) 1.14
Therapeutic targeting of PELP1 prevents ovarian cancer growth and metastasis. Clin Cancer Res (2011) 1.14
EphA2 overexpression promotes ovarian cancer growth. Cancer Biol Ther (2008) 1.13
Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev (2013) 1.12
MicroRNAs as therapeutic targets in chemoresistance. Drug Resist Updat (2013) 1.11
Eph receptors in breast cancer: roles in tumor promotion and tumor suppression. Breast Cancer Res (2008) 1.10
Hypoxia-mediated downregulation of miRNA biogenesis promotes tumour progression. Nat Commun (2014) 1.10
RNAi: a potential new class of therapeutic for human genetic disease. Hum Genet (2011) 1.10
Therapeutic microRNA strategies in human cancer. AAPS J (2009) 1.10
Hematogenous metastasis of ovarian cancer: rethinking mode of spread. Cancer Cell (2014) 1.09
Targeting the PELP1-KDM1 axis as a potential therapeutic strategy for breast cancer. Breast Cancer Res (2012) 1.08
Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst (2011) 1.08
MicroRNA therapeutics: principles, expectations, and challenges. Chin J Cancer (2011) 1.07
Chitosan hydrogel for localized gene silencing. Cancer Biol Ther (2011) 1.07
miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13. Nat Commun (2014) 1.06
Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One (2012) 1.06
Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res (2012) 1.05
Targeting aurora kinase with MK-0457 inhibits ovarian cancer growth. Clin Cancer Res (2008) 1.04
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors. Invest New Drugs (2012) 1.03
miRNA Deregulation in Cancer Cells and the Tumor Microenvironment. Cancer Discov (2016) 1.03
Silencing survivin splice variant 2B leads to antitumor activity in taxane--resistant ovarian cancer. Clin Cancer Res (2011) 1.03
2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun (2014) 1.03
Converging evidence for efficacy from parallel EphB4-targeted approaches in ovarian carcinoma. Mol Cancer Ther (2010) 1.02
Effects of cancer-associated EPHA3 mutations on lung cancer. J Natl Cancer Inst (2012) 1.02
Identification of FGFR4 as a potential therapeutic target for advanced-stage, high-grade serous ovarian cancer. Clin Cancer Res (2013) 1.02
Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver. Oncogene (2008) 1.01
Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev (2015) 1.01
Enhancing chemotherapy response with Bmi-1 silencing in ovarian cancer. PLoS One (2011) 1.01
Novel strategies for reversing platinum resistance. Drug Resist Updat (2009) 1.00
EphA2 as a promoter of melanoma tumorigenicity. Cancer Biol Ther (2009) 1.00
Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98
Toxicological considerations when creating nanoparticle-based drugs and drug delivery systems. Expert Opin Drug Metab Toxicol (2011) 0.98
Regulation of tumor initiation and metastatic progression by Eph receptor tyrosine kinases. Adv Cancer Res (2012) 0.98
Eph receptors and ephrins as targets for cancer therapy. J Cell Mol Med (2012) 0.98
Structure-activity relationship analysis of peptides targeting the EphA2 receptor. Biochemistry (2010) 0.97
c-Jun-NH2-kinase-1 inhibition leads to antitumor activity in ovarian cancer. Clin Cancer Res (2009) 0.97
Hsp90 as a gatekeeper of tumor angiogenesis: clinical promise and potential pitfalls. J Oncol (2010) 0.97
Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections. Theranostics (2014) 0.96
Cationic lipid nanoparticles for therapeutic delivery of siRNA and miRNA to murine liver tumor. Nanomedicine (2013) 0.95
Clinical and biological relevance of enhancer of zeste homolog 2 in triple-negative breast cancer. Hum Pathol (2012) 0.95
Antibody-dependent cell-mediated cytotoxicity effector-enhanced EphA2 agonist monoclonal antibody demonstrates potent activity against human tumors. Neoplasia (2009) 0.95
A general RNA motif for cellular transfection. Mol Ther (2012) 0.94
Delivery of gene silencing agents for breast cancer therapy. Breast Cancer Res (2013) 0.94
Vectoring siRNA therapeutics into the clinic. Nat Rev Clin Oncol (2010) 0.94
Vascular endothelial growth factor (VEGF) pathway as a therapeutic target in gynecologic malignancies. Gynecol Oncol (2007) 0.93
Combination therapy with HSP90 inhibitor 17-DMAG reconditions the tumor microenvironment to improve recruitment of therapeutic T cells. Cancer Res (2012) 0.92
Therapeutic silencing of KRAS using systemically delivered siRNAs. Mol Cancer Ther (2014) 0.92
Recent developments in nanoparticle-based siRNA delivery for cancer therapy. Biomed Res Int (2013) 0.92
Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy (2007) 20.92
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Dicer, Drosha, and outcomes in patients with ovarian cancer. N Engl J Med (2008) 8.77
Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. JAMA (2011) 6.81
Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma. Nat Med (2006) 6.18
MicroRNAs in body fluids--the mix of hormones and biomarkers. Nat Rev Clin Oncol (2011) 5.46
Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer (2011) 5.28
Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol (2005) 4.77
The influence of bio-behavioural factors on tumour biology: pathways and mechanisms. Nat Rev Cancer (2006) 4.27
Early events in the pathogenesis of epithelial ovarian cancer. J Clin Oncol (2008) 3.68
Chromosome stability, in the absence of apoptosis, is critical for suppression of tumorigenesis in Trp53 mutant mice. Nat Genet (2003) 3.61
Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med (2012) 3.54
Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol (2004) 3.49
RNA interference in the clinic: challenges and future directions. Nat Rev Cancer (2010) 3.43
The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res (2010) 3.36
Regulation of tumor angiogenesis by EZH2. Cancer Cell (2010) 3.10
Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res (2004) 2.96
Beta-blocker use is associated with improved relapse-free survival in patients with triple-negative breast cancer. J Clin Oncol (2011) 2.90
Focal adhesion kinase targeting using in vivo short interfering RNA delivery in neutral liposomes for ovarian carcinoma therapy. Clin Cancer Res (2006) 2.86
Sustained small interfering RNA delivery by mesoporous silicon particles. Cancer Res (2010) 2.80
Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy (2010) 2.62
Stress-related mediators stimulate vascular endothelial growth factor secretion by two ovarian cancer cell lines. Clin Cancer Res (2003) 2.50
Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res (2005) 2.48
Mismatch repair gene expression defects contribute to microsatellite instability in ovarian carcinoma. Cancer (2003) 2.48
Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. J Natl Cancer Inst (2008) 2.40
Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. J Natl Cancer Inst (2008) 2.37
Integrated analyses identify a master microRNA regulatory network for the mesenchymal subtype in serous ovarian cancer. Cancer Cell (2013) 2.34
Norepinephrine up-regulates the expression of vascular endothelial growth factor, matrix metalloproteinase (MMP)-2, and MMP-9 in nasopharyngeal carcinoma tumor cells. Cancer Res (2006) 2.32
Computational identification of gene-social environment interaction at the human IL6 locus. Proc Natl Acad Sci U S A (2010) 2.31
Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer. Mol Cancer Ther (2010) 2.27
Latest research and treatment of advanced-stage epithelial ovarian cancer. Nat Rev Clin Oncol (2013) 2.24
Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res (2010) 2.19
Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer. J Clin Oncol (2004) 2.10
Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis. J Clin Invest (2010) 2.04
Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-kappaB pathway. Clin Cancer Res (2007) 1.98
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. Proc Natl Acad Sci U S A (2011) 1.97
Platelets increase the proliferation of ovarian cancer cells. Blood (2012) 1.97
Clinical behavior of stage II-IV low-grade serous carcinoma of the ovary. Obstet Gynecol (2006) 1.93
Therapeutic efficacy of a novel focal adhesion kinase inhibitor TAE226 in ovarian carcinoma. Cancer Res (2007) 1.90
A novel platform for detection of CK+ and CK- CTCs. Cancer Discov (2011) 1.88
Therapeutic significance of elevated tissue transglutaminase expression in pancreatic cancer. Clin Cancer Res (2008) 1.88
Efficacy and antivascular effects of EphA2 reduction with an agonistic antibody in ovarian cancer. J Natl Cancer Inst (2006) 1.87
Molecular pathways: beta-adrenergic signaling in cancer. Clin Cancer Res (2011) 1.84
EphA2 expression is associated with aggressive features in ovarian carcinoma. Clin Cancer Res (2004) 1.80
Psychosocial factors and interleukin-6 among women with advanced ovarian cancer. Cancer (2005) 1.79
Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. J Natl Cancer Inst (2013) 1.78
HLA class I antigen processing machinery component expression and intratumoral T-Cell infiltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res (2008) 1.77
Activated SRC protein tyrosine kinase is overexpressed in late-stage human ovarian cancers. Gynecol Oncol (2003) 1.75
Surgical stress promotes tumor growth in ovarian carcinoma. Clin Cancer Res (2009) 1.73
Silencing of Bcl-2 expression by small interfering RNA induces autophagic cell death in MCF-7 breast cancer cells. Autophagy (2008) 1.71
Targeting pericytes with a PDGF-B aptamer in human ovarian carcinoma models. Cancer Biol Ther (2010) 1.71
Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol (2007) 1.69
Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma. Cancer Res (2007) 1.68
Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res (2007) 1.66
Depression, social support, and beta-adrenergic transcription control in human ovarian cancer. Brain Behav Immun (2008) 1.66
Phase 1-2 study of docetaxel plus aflibercept in patients with recurrent ovarian, primary peritoneal, or fallopian tube cancer. Lancet Oncol (2011) 1.65
Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. Cancer Res (2008) 1.65
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Focal adhesion kinase silencing augments docetaxel-mediated apoptosis in ovarian cancer cells. Clin Cancer Res (2005) 1.63
Lymphatic mapping and sentinel node biopsy in women with high-risk endometrial cancer. Gynecol Oncol (2006) 1.63
Src activation by β-adrenoreceptors is a key switch for tumour metastasis. Nat Commun (2013) 1.62
Tissue macroarray: a simple and cost-effective method for high-throughput studies. Appl Immunohistochem Mol Morphol (2003) 1.61
Therapeutic Targeting of ATP7B in Ovarian Carcinoma. Clin Cancer Res (2009) 1.61
Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. J Clin Oncol (2012) 1.61
Recurrent low-grade serous ovarian carcinoma is relatively chemoresistant. Gynecol Oncol (2009) 1.61